Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Biological E. Limited operates as a biological products company that develops, manufactures, markets, and supplies preventive medicines, vaccines, and pharmaceutical products.
Biological E. Limited, is an unlisted public company incorporated on 10 December, 1953. It is classified as a public limited company and is located in , . It's authorized share capital is INR 5.00 cr and the total paid-up capital is INR 4.95 cr.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Managing Director | Mahima Datla
Shareholder
|
00965039 | 12 years |
Director | Ippagunta Yasodhara Rama Krishna Rao | 00481367 | 8 years |
Whole-time Director | Rudaraju Anand Kumar | 07964480 | 8 years |
Additional Director | Peter Baron Piot | 09015343 | 1 years |
Whole-Time Director | Narender Dev Mantena | 01000558 | 1 years |
Additional Director | Venkata Subbaraju Penmetsa | 00028230 | 1 years |
Additional Director | Narsing Rao Singayapally | 00800362 | 1 years |
Whole-time Director | Indira Smriti Rajupusapati
Shareholder
|
00482381 | 2 years |
Whole-time Director | Mantena Purnima
Shareholder
|
00965007 | 2 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | 921.2 | 1,274.9 | 2,475.8 | 3,659.4 | 2,401.1 |
Operating profit | 36.2 | 225.4 | 652.8 | 1,175.6 | 603.8 |
Net profit | 100.9 | 169.7 | 392.9 | 904.1 | 749.3 |
Gross margin | 85.3 | 85.9 | 82.6 | 77.0 | 83.9 |
Operating margin | 3.9 | 17.7 | 26.4 | 32.1 | 25.1 |
Net margin | 9.4 | 12.0 | 15.2 | 24.0 | 29.4 |
Networth | 1,565.9 | 1,729.6 | 2,120.0 | 3,003.2 | 3,758.2 |
Borrowings | 866.6 | 654.3 | 1,781.9 | 1,924.5 | 1,792.6 |
Assets | 2,851.6 | 3,480.0 | 7,395.5 | 8,058.1 | 7,499.0 |
Debt to equity | 0.6 | 0.4 | 0.8 | 0.6 | 0.5 |
Current ratio | 3.2 | 1.6 | 1.2 | 1.2 | 1.6 |
ROE | 6.4 | 9.8 | 18.5 | 30.1 | 19.9 |
Days payable | 392.0 | 322.0 | 210.0 | 309.0 | 586.0 |
WC days | 324.0 | 145.0 | 95.0 | 70.0 | 222.0 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 |
Reserves | 1,560.9 | 1,724.6 | 2,115.1 | 2,998.3 | 3,753.3 |
Borrowings + | 866.6 | 654.3 | 1,781.9 | 1,924.5 | 1,792.6 |
Long term borrowings | 797.3 | 654.3 | 660.3 | 706.1 | 604.8 |
Short term borrowings | 69.3 | - | 1,121.6 | 1,218.4 | 1,187.8 |
Trade payables + | 145.7 | 158.6 | 248.1 | 714.5 | 621.3 |
Days payable | 392.0 | 322.0 | 210.0 | 309.0 | 586.0 |
Other liabilities + | 419.1 | 1,096.2 | 3,493.5 | 3,130.4 | 1,948.2 |
Other non-current liabilities | 109.8 | 276.7 | 675.6 | 431.0 | 648.4 |
Other current liabilities | 163.5 | 660.8 | 2,569.8 | 1,984.8 | 678.4 |
Total liabilities | 2,851.6 | 3,480.0 | 7,395.5 | 8,058.1 | 7,499.0 |
Fixed Assets + | 1,309.6 | 1,598.2 | 2,229.7 | 2,523.0 | 2,600.6 |
Tangible assets | 1,136.6 | 1,079.5 | 1,319.8 | 1,635.9 | 1,857.0 |
CWIP | 169.0 | 513.4 | 793.9 | 771.2 | 594.8 |
Intangible assets | 4.0 | 5.3 | 116.0 | 115.9 | 148.8 |
LT loans and advances | 10.4 | 13.1 | 13.4 | 16.8 | 18.5 |
Other non-current assets | 335.1 | 544.3 | 566.6 | 894.6 | 934.7 |
Current assets + | 1,196.5 | 1,324.5 | 4,585.8 | 4,623.7 | 3,945.2 |
Inventories | 646.8 | 797.6 | 3,186.9 | 2,969.8 | 2,895.2 |
Trade receivables | 188.2 | 120.9 | 748.1 | 1,310.3 | 433.9 |
Cash and cash equivalents | 35.4 | 98.3 | 40.7 | 34.3 | 36.8 |
ST loans and advances | 18.7 | 52.4 | 21.2 | 23.5 | - |
Other current assets | 307.3 | 255.3 | 588.9 | 285.9 | 579.4 |
Total assets | 2,851.6 | 3,480.0 | 7,395.5 | 8,058.1 | 7,499.0 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales + | 921.2 | 1,274.9 | 2,475.8 | 3,659.4 | 2,401.1 |
Sales growth % | -1.41 | 38.39 | 94.2 | 47.81 | -34.39 |
Expenses + | 972.4 | 1,173.0 | 1,986.1 | 2,787.8 | 2,143.0 |
Cost of goods | 135.7 | 179.9 | 430.6 | 842.9 | 386.9 |
Employee cost | 245.7 | 297.7 | 415.1 | 454.0 | 476.3 |
Other costs | 503.6 | 571.8 | 977.2 | 1,186.9 | 934.1 |
Operating profit + | 36.2 | 225.4 | 652.8 | 1,175.6 | 603.8 |
Operating margin % | 3.9 | 17.7 | 26.4 | 32.1 | 25.1 |
Other income | 155.2 | 143.2 | 112.0 | 110.5 | 144.2 |
Interest | 32.2 | 42.2 | 65.3 | 178.5 | 189.7 |
Depreciation | 55.2 | 81.4 | 97.9 | 125.5 | 155.9 |
Exceptional items | 47.3 | - | - | -314.1 | 508.3 |
Profit before tax | 151.3 | 245.1 | 601.7 | 668.0 | 910.7 |
Tax | 50.4 | 75.3 | 208.8 | -236.1 | 161.4 |
Profit - disc. ops | - | - | - | - | - |
Net profit | 100.9 | 169.7 | 392.9 | 904.1 | 749.3 |
Net margin % | 9.4 | 12.0 | 15.2 | 24.0 | 29.4 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | 0.6 | 0.4 | 0.8 | 0.6 | 0.5 |
Net Debt/Equity | 0.5 | 0.3 | 0.8 | 0.6 | 0.5 |
Total Debt/Assets | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
Total Assets/Equity | 1.8 | 2.0 | 3.5 | 2.7 | 2.0 |
Liquidity + | |||||
Current Ratio | 3.2 | 1.6 | 1.2 | 1.2 | 1.6 |
Quick Ratio | 1.4 | 0.6 | 0.4 | 0.4 | 0.4 |
Interest Coverage | 1.1 | 5.3 | 10.0 | 6.6 | 3.2 |
Performance | |||||
Gross Margin | 85.3 | 85.9 | 82.6 | 77.0 | 83.9 |
Operating Margin | 3.9 | 17.7 | 26.4 | 32.1 | 25.1 |
Net Margin | 9.4 | 12.0 | 15.2 | 24.0 | 29.4 |
Return + | |||||
Return on Equity | 6.4 | 9.8 | 18.5 | 30.1 | 19.9 |
Pre-tax ROCE | -0.9 | 6.8 | 19.3 | 32.5 | 11.0 |
Return on Assets | 3.5 | 4.9 | 5.3 | 11.2 | 10.0 |
Pre-tax ROIC | -0.8 | 6.3 | 14.4 | 21.5 | 8.1 |
Efficiency + | |||||
Days Payable | 392.0 | 322.0 | 210.0 | 309.0 | 586.0 |
Days Inventory | 1,740.0 | 1,618.0 | 2,701.0 | 1,286.0 | 2,731.0 |
Days Receivable | 75.0 | 35.0 | 110.0 | 131.0 | 66.0 |
Fixed Asset Turnover | 0.7 | 0.8 | 1.1 | 1.4 | 0.9 |
Total Asset Turnover | 0.3 | 0.4 | 0.3 | 0.5 | 0.3 |
Working Capital | |||||
Cash Conversion Cycle | 1,423.0 | 1,331.0 | 2,601.0 | 1,108.0 | 2,211.0 |
Working Capital Days | 324.0 | 145.0 | 95.0 | 70.0 | 222.0 |
State Bank of India
No. of Loans: 1
Total Amount : 813.3 cr
HDFC Bank Limited
No. of Loans: 2
Total Amount : 580.0 cr
Axis Bank Limited
No. of Loans: 3
Total Amount : 467.1 cr
CitiBank N.A.
No. of Loans: 2
Total Amount : 417.8 cr
BANK OF BARODA ,
No. of Loans: 1
Total Amount : 300.0 cr
UNIT TRUST OF INDIA
No. of Loans: 2
Total Amount : 2.1 cr
The Vysya Bank Limited
No. of Loans: 1
Total Amount : 0.1 cr
Uttar Pradesh Financial Corporation
No. of Loans: 1
Total Amount : 0.0 cr
UTTAR PRADESH FINANCIAL CORP.
No. of Loans: 1
Total Amount : 0.0 cr
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
BIOTECH MEDICALS PRIVATE LIMITED | Telangana | 1999 | ₹ 1.0 Cr |
B.E. INVESTMENT AND FINANCE PVT LTD | Telangana | 1987 | ₹ 1.0 L |
BE Vaccines PTE Limited, Singapore | Singapore | - | - |
VAXENIC INDIA PRIVATE LIMITED | Telangana | 2015 | ₹ 1.0 L |
BE Pharmaceuticals AG Zug, Switzerland | Switzerland | - | - |
BE PHARMACEUTICALS PRIVATE LIMITED | Telangana | 2011 | ₹ 5.0 Cr |
BE PHARMACEUTICALS AG ZUG, SWITZERLAND | Switzerland | - | - |
Read more
The incorporation date of BIOLOGICAL E. LIMITED is 10 December, 1953
The authorized share capital of BIOLOGICAL E. LIMITED is INR ₹ 5.0 Cr.
The paid-up capital of BIOLOGICAL E. LIMITED is INR ₹ 5.0 Cr.
The registered address of BIOLOGICAL E. LIMITED is 18/1 AND 3,AZAMABAD, HYDERABAD, ANDHRA PRADESH, Telangana, India, 500020 - 500020
The CIN number of BIOLOGICAL E. LIMITED is U01120TG1953PLC001095.